Neurizon Advances NUZ-001 Development, Secures AU$7.1 million Placement and AU$20 million Funding Facility
Neurizon Therapeutics Limited (ASX: NUZ) has reported its half-year results for the period ended 31 December 2025, highlighting significant clinical, regulatory, and funding milestones for its lead asset NUZ-001 in Amyotrophic Lateral Sclerosis (ALS). The Company’s Investigational New Drug application was accepted by the U.S. FDA following resolution of a prior clinical hold, clearing the pathway for participation in the HEALEY ALS Platform Trial. Positive top-line data from the 12-month Phase 1 Open Label Extension study demonstrated favourable long-term safety and tolerability, with exploratory survival signals supporting dose selection for late-stage evaluation. During the period, Neurizon secured a AU$7.1 million placement at AU$0.08 per share and established a AU$20 million convertible note facility with Obsidian Global to fund trial execution. An Advance & Overseas Finding and R&D Tax Incentive supports non-dilutive funding. Cash at period end was AU$7.9 million, with additional capital raised post-period strengthening the balance sheet for ongoing clinical advancement.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Neurizon Advances NUZ-001 Development, Secures AU$7.1 million Placement and AU$20 million Funding Facility
Neurizon Therapeutics Limited (ASX: NUZ) has reported its half-year results for the period ended 31 December 2025, highlighting significant clinical, regulatory, and funding milestones for its lead asset NUZ-001 in Amyotrophic Lateral Sclerosis (ALS). The Company’s Investigational New Drug application was accepted by the U.S. FDA following resolution of a prior clinical hold, clearing the pathway for participation in the HEALEY ALS Platform Trial. Positive top-line data from the 12-month Phase 1 Open Label Extension study demonstrated favourable long-term safety and tolerability, with exploratory survival signals supporting dose selection for late-stage evaluation. During the period, Neurizon secured a AU$7.1 million placement at AU$0.08 per share and established a AU$20 million convertible note facility with Obsidian Global to fund trial execution. An Advance & Overseas Finding and R&D Tax Incentive supports non-dilutive funding. Cash at period end was AU$7.9 million, with additional capital raised post-period strengthening the balance sheet for ongoing clinical advancement.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au